Personnel Information

写真a

SHIMOKAWA Teruhiko


Homepage URL

https://tmdu-oi.jp

Research Areas, Keywords

Drug Discovery Research, Clinical Development, Alliance
To the head of this page.▲

Graduate School 【 display / non-display 】

  • Nagoya City University, Department of Pharmaceutical Sciences, Biopharmaceutical Chemistry Research Lab, Doctor's Course, 1989.03, Completed

To the head of this page.▲

Degree 【 display / non-display 】

  • Ph.D., Nagoya City University

To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2023.04
    -
    Now
    Tokyo Medical and Dental University， -， -， Project Professor
  • 2023.03
    　
    　
    Tokyo Medical and Dental University， -， -， Creative Manager(Teaching Staff)
  • 2021.12
    -
    2023.02
    Tokyo Medical and Dental University， Institute of Open Innovation， Creative Manager(Teaching Staff)
To the head of this page.▲

External Career 【 display / non-display 】

  • 1999.12
    　
    　
    The Johns Hopkins University, School of Medicine, Department of Biological Chemistry, Research Fellow
  • 1989.08
    　
    　
    Michigan State University, Department of Biochemistry, Post-doctoral Research Fellow
  • 2020.03
    　
    　
    AMED,, Department of Intellectual Property, IP Consultant
  • 2012.04
    　
    　
    Astellas Pharma Inc., Department of Clinical Development, Global Project Management Lead, GPML
  • 2005.04
    　
    　
    Astellas Pharma Inc., Department of Drug Discovery Research, Principal Investigator, Director
  • 1991.11
    　
    　
    Yamanouchi Pharmaceutical Co., Ltd., Department of Drug Discovery Research, Principal Investigator, Research Manager
  • 1989.04
    　
    　
    Japan Society for the Promotion of Science, Research Fellowship for Young Scientists

▼display all

To the head of this page.▲

Academic Society Affiliations 【 display / non-display 】

  • The Endocrine Society, ENDO

  • American Heart Association, AHA

  • Intellectual Property Association of Japan

  • The Pharmaceutical Society of Japan

  • The Japan Atherosclerosis Society

  • The Japanese Conference on the Biochemistry of Lipids

  • The Japanese Society for Phage Therapy

▼display all

To the head of this page.▲

Academic Activity 【 display / non-display 】

  • 2024.04
    -
    Now
    Suprime Court Expert Committee Member, Intellectual Property High Court
  • 2024.04
    -
    Now
    Japan Agency for Medical Research and Development, AMED Expert Committee Member, Project for Strengthening Drug Discovery Venture Ecosystem
  • 2023.04
    -
    Now
    Japan Agency for Medical Research and Development, AMED Program Officer PO, Research Project for Practical Application of Hepatitis B Drug Discovery
  • 2023.04
    -
    Now
    Japan Agency for Medical Research and Development, AMED Program Officer PO, Research Project on Emergency Measures to Overcome Hepatitis
  • 2022.01
    -
    2023.03
    Japan Agency for Medical Research and Development AMED Program Officer, PO
  • 2022.04
    -
    2024.03
    Japan Agency for Medical Research and Development AMED Evaluation Committee Member
  • 2022.03
    　
    　
    Japan Agency for Medical Research and Development AMED Science and Technology Investigator

▼display all

To the head of this page.▲

Research Areas 【 display / non-display 】

  • Molecular biology

  • Metabolism and endocrinology

  • Pathological biochemistry

  • Pharmacology

  • Cell biology

  • Pharmaceutical chemistry and drug development sciences

  • Nephrology

▼display all

To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Tanaka H, Yoshida S, Minoura H, Negoro K, Shimaya A, Shimokawa T, Shibasaki M. Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion. Life Sciences. 2014.01; 94 (2): 115-21. ( PubMed, DOI )

  2. Suwa A, Yoshino M, Kurama T, Shimokawa T, Aramori I. Glucose regulates RMI1 expression through the E2F pathways in adipose cells. Endocrine. 2011.08; 40 (1): 56-61. ( PubMed, DOI )

  3. Tanaka H, Shimaya A, Kiso T, Kuramochi T, Shimokawa T, Shibasaki M. Enhanced insulin secretion and sensitization in diabetic mice on chronic treatment with a transient receptor potential vanilloid 1 antagonist. Life Sciences. 2011.03; 88 (11-12): 559-63. ( PubMed, DOI )

  4. Suwa A, Shimokawa T. Emerging targets for the treatment of obesity. The FEBS Journal. 2011.02; 278 (4): 551. ( PubMed, DOI )

  5. Suwa A, Kurama T, Shimokawa T. Adipocyte hyperplasia and RMI1 in the treatment of obesity. The FEBS Journal. 2011.02; 278 (4): 565-9. ( PubMed, DOI )

  6. Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A, Shimokawa T, Shibasaki M. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Molecular Pharmacology. 2010.11; 78 (5): 961-70. ( PubMed, DOI )

  7. Tanaka H, Nagashima T, Shimaya A, Urano Y, Shimokawa T, Shibasaki M. Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice. European Journal of Pharmacology. 2010.10; 645 (1-3): 185-91. ( PubMed, DOI )

  8. Suwa A, Kurama T, Yamamoto T, Sawada A, Shimokawa T, Aramori I. Glucose metabolism activation by SHIP2 inhibitors via up-regulation of GLUT1 gene in L6 myotubes. European Journal of Pharmacology. 2010.09; 642 (1-3): 177-82. ( PubMed, DOI )

  9. Suwa A, Kurama T, Shimokawa T. SHIP2 and its involvement in various diseases. Expert Opinion on Therapeutic Targets. 2010.07; 14 (7): 727-37. ( PubMed, DOI )

  10. Suwa A, Yoshino M, Yamazaki C, Naitou M, Fujikawa R, Matsumoto S, Kurama T, Shimokawa T, Aramori I. RMI1 deficiency in mice protects from diet and genetic-induced obesity. The FEBS Journal. 2010.02; 277 (3): 677-86. ( PubMed, DOI )

  11. A. Suwa, T. Yamamoto, A. Sawada, K. Minoura, N. Hosogai, A. Tahara, T. Kurama, T. Shimokawa, I. Aramori. Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2: RESEARCH PAPER British Journal of Pharmacology. 2009.10; 158 (3): 879-887. ( PubMed, DOI )

  12. Wolfgang MJ, Cha SH, Millington DS, Cline G, Shulman GI, Suwa A, Asaumi M, Kurama T, Shimokawa T, Lane MD. Brain-specific carnitine palmitoyl-transferase-1c: role in CNS fatty acid metabolism, food intake, and body weight. Journal of Neurochemistry. 2008.05; 105 (4): 1550-9. ( PubMed, DOI )

  13. Wolfgang MJ, Kurama T, Dai Y, Suwa A, Asaumi M, Matsumoto S, Cha SH, Shimokawa T, Lane MD. The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis. Proceedings of the National Academy of Sciences of the United States of America. 2006.05; 103 (19): 7282-7. ( PubMed, DOI )

  14. S. Terada, K. Kawanaka, M. Goto, T. Shimokawa, I. Tabata. Effects of high-intensity intermittent swimming on PGC-1α protein expression in rat skeletal muscle Acta Physiologica Scandinavica. 2005.05; 184 (1): 59-65. ( PubMed, DOI )

  15. M. Kato, A. Suwa, T. Shimokawa. Glucose catabolic gene mRNA levels in skeletal muscle exhibit non-coordinate expression in hyperglycemic mice Hormone and Metabolic Research. 2004.08; 36 (8): 513-518. ( PubMed, DOI )

  16. Hori Shinichiro, Yamada Makoto, Ohtani Sachiko, Hori Chiyo, Yokomizo Tadahiro, Webb Timothy, Shimokawa Teruhiko. Myonase is Localized in Skeletal Muscle Myofibrils. The Journal of Biochemistry. 2002.09; 132 (3): 417-425. ( ichushi )

  17. Terada S, Goto M, Kato M, Kawanaka K, Shimokawa T, Tabata I. Effects of low-intensity prolonged exercise on PGC-1 mRNA expression in rat epitrochlearis muscle. Biochemical and Biophysical Research Communications. 2002.08; 296 (2): 350-4. ( PubMed, DOI )

  18. Kumar MV, Shimokawa T, Nagy TR, Lane MD. Differential effects of a centrally acting fatty acid synthase inhibitor in lean and obese mice. Proceedings of the National Academy of Sciences of the United States of America. 2002.02; 99 (4): 1921-5. ( PubMed, DOI )

  19. Shimokawa T, Kumar MV, Lane MD. Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides. Proceedings of the National Academy of Sciences of the United States of America. 2002.01; 99 (1): 66-71. ( PubMed, DOI )

  20. Teruhiko Shimokawa, Mitsuhiro Kagami, Miyuki Kato, Eiji Kurosaki, Masayuki Shibasaki, Masao Katoh. Effect of YM-126414 on glucose uptake and redistribution of glucose transporter isotype 4 in muscle cells European Journal of Pharmacology. 2000.12; 410 (1): 1-5. ( PubMed, DOI )

  21. Masahide Goto, Shin Terada, Miyuki Kato, Masao Katoh, Toshiko Yokozeki, Izumi Tabata, Teruhiko Shimokawa. cDNA cloning and mRNA analysis of PGC-1 in epitrochlearis muscle in swimming-exercised rats Biochemical and Biophysical Research Communications. 2000.08; 274 (2): 350-354. ( PubMed, DOI )

  22. Teruhiko Shimokawa, Miyuki Kato, Mitsuhiro Kagami, Yoshitaka Ueda, Eiji Kurosaki, Tatsuya Maruyama, Masayuki Shibasaki, Masao Katoh. Glucose uptake stimulator YM-138552 activates gene expression and translocation of glucose transporter isotype 4 Drug Development Research. 2000; 51 (1): 43-48. ( DOI )

  23. Cha Seung Hun, Kyoko Hasegawa, Terue Kawabata, Miyuki Kato, Teruhiko Shimokawa, Yasuo Kagawa. Increased uncoupling protein2 mRNA in white adipose tissue, and decrease in leptin, visceral fat, blood glucose, and cholesterol in KK-A(y) mice fed with eicosapentaenoic and docosahexaenoic acids in addition to linolenic acid Biochemical and Biophysical Research Communications. 1999.05; 259 (1): 85-90. ( PubMed, DOI )

  24. Shoichiro Goto, Teruhiko Shimokawa. Effect of the hypocholesterolemic agent YM-16638 on cholesterol biosynthesis activity and apolipoprotein B secretion in HepG2 and monkey liver Japanese Journal of Pharmacology. 1999; 79 (1): 75-82. ( PubMed, DOI )

  25. Teruhiko Shimokawa, Miyuki Kato, Yuka Watanabe, Reiko Hirayama, Eiji Kurosaki, Hisataka Shikama, Seiichi Hashimoto. In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in skeletal muscle of hyperglycemic KK mice Biochemical and Biophysical Research Communications. 1998.10; 251 (1): 374-378. ( PubMed, DOI )

  26. Teruhiko Shimokawa, Miyuki Kato, Osamu Ezaki, Seiichi Hashimoto. Transcriptional regulation of muscle-specific genes during myoblast differentiation Biochemical and Biophysical Research Communications. 1998.05; 246 (1): 287-292. ( PubMed, DOI )

  27. Teruhiko Shimokawa, Shoichiro Goto, Motoko Ida, Masahide Goto, Satomi Nishijima, Tatsuhiko Kodama. Hypocholesterolemic effects of the LDL receptor gene transcriptional upregulator CP-230821 Journal of Biochemistry. 1998.04; 123 (4): 596-601. ( PubMed, DOI )

  28. Teruhiko Shimokawa, Miyuki Kato, Koichi Shioduka, Jun Irie, Osamu Ezaki. Effect of triiodothyronine on muscle cell differentiation and blood glucose level in hyperglycemic KK mice Biochemical and Biophysical Research Communications. 1997.06; 235 (3): 790-793. ( PubMed, DOI )

  29. Teruhiko Shimokawa, Shoichiro Goto, Tohru Ugawa, Nami Hisamichi, Shin Naganuma, Yuichi Iizumi, Noboru Sato, Toichi Takenaka, Tatsuhiko Kodama. Cholesterol-lowering effect of YM-16638 in cynomolgus monkeys Drug Development Research. 1996.06; 38 (2): 86-92. ( DOI )

  30. Shoichiro Goto, Teruhiko Shimokawa, Toru Ugawa, Nami Hisamichi, Youichi Masuyama, Yuichi Iizumi, Noboru Sato, Toichi Takenaka, Tatsuhiki Kodama. Species specificity in the blood cholesterol-lowering effect of YM-16638 British Journal of Pharmacology. 1996; 118 (1): 174-178. ( PubMed, DOI )

  31. T. Shimokawa, T. Ugawa, S. Goto, N. Sato, T. Takenaka, T. Kodama. Effect of YM-16638, an orally active leukotriene antagonist, on alanine aminotransferase activity in-vitro and in-vivo Pharmaceutical Sciences. 1996; 2 (10): 483-486.

  32. Yoshiki Kawabe, Teruhiko Shimokawa, Akiyo Matsumoto, Makoto Honda, Yoichiro Wada, Yoshio Yazaki, Akira Endo, Hiroshige Itakura, Tatsuhiko Kodama. The molecular mechanism of the induction of the low density lipoprotein receptor by chenodeoxycholic acid in cultured human cells Biochemical and Biophysical Research Communications. 1995.03; 208 (1): 405-411. ( PubMed, DOI )

  33. T. Shimokawa, Y. Kawabe, M. Honda, Y. Yazaki, A. Matsumoto, H. Itakura, T. Kodama. Determination of mRNA levels of cholesterol biosynthesis enzymes and LDL receptor using ribonuclease protection assay Journal of Lipid Research. 1995; 36 (9): 1919-1924. ( PubMed )

  34. Teruhiko Shimokawa, William L. Smith. Expression of prostaglandin endoperoxide synthase-1 in a baculovirus system Biochemical and Biophysical Research Communications. 1992.03; 183 (3): 975-982. ( PubMed, DOI )

  35. T. Shimokawa, W. L. Smith. Prostaglandin endoperoxide synthase. The aspirin acetylation region Journal of Biological Chemistry. 1992; 267 (17): 12387-12392. ( PubMed )

  36. Keiko Sakai, Teruhiko Shimokawa, Tetsuyuki Kobayashi, Harumi Okuyama. Lipid Lowering Effects of High Linoleate and High a-Linolenate Diets in Rats and Mice: Consequence of Long-Term Feedings Chemical and Pharmaceutical Bulletin. 1992; 40 (8): 2129-2132. ( PubMed, DOI )

  37. TAKAUE, Y; WATANABE, T; HOSHI, Y; ABE, T; MATSUNAGA, K; SAITO, S; HIRAO, A; KAWANO, Y; NINOMIYA, T; KURODA, Y; KOYAMA, T; SUZUE, T; SHIMOKAWA, T; UCHIYAMA, H; WATANABE, A; MATSUSHITA, T; KIKUTA, A; YOKOBAYASHI, A; MURAKAMI, R; MANABE, A; HOSOYA, R; OHIRA, M; FUJIMOTO, T. EFFECTIVENESS OF HIGH-DOSE MCNU THERAPY AND HEMATOPOIETIC STEM-CELL AUTOGRAFTS TREATMENT OF CHILDHOOD ACUTE-LEUKEMIA LYMPHOMA WITH HIGH-RISK FEATURES CANCER. 1991.04; 67 (7): 1830-1837. ( PubMed, DOI )

  38. T. Shimokawa, W. L. Smith. Essential histidines of prostaglandin endoperoxide synthase: His-309 is involved in heme binding Journal of Biological Chemistry. 1991; 266 (10): 6168-6173. ( PubMed )

  39. W. L. Smith, D. L. DeWitt, T. Shimokawa. The aspirin and heme binding sites of PGG/H synthase. Advances in prostaglandin, thromboxane, and leukotriene research. 1991; 21 A 77-80. ( PubMed )

  40. William L. Smith, David L. DeWitt, Teruhiko Shimokawa, Stacey A. Kraemer, Elizabeth A. Meade. Molecular basis for the inhibition of prostanoid biosynthesis by nonsteroidal anti-inflammatory agents Stroke. 1990.12; 21 (12): IV-24. ( PubMed )

  41. T. Shimokawa, R. J. Kulmacz, D. L. DeWitt, W. L. Smith. Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis Journal of Biological Chemistry. 1990; 265 (33): 20073-20076. ( PubMed )

  42. W. L. Smith, D. L. DeWitt, S. A. Kraemer, M. J. Andrews, T. Hla, T. Maciag, T. Shimokawa. Structure-function relationships in sheep, mouse, and human prostaglandin endoperoxide G/H synthases. Advances in prostaglandin, thromboxane, and leukotriene research. 1990; 20 14-21. ( PubMed )

  43. Hiromi Hayashi, Koji Ueno, Takamitsu Hori, Yukio Naito, Teruhiko Shimokawa, Harumi Okuyama. Hypertension does not stimulate the development of hypercholesterolemia or fatty liver induced by a high cholesterol/cholate diet in rats Chemical and Pharmaceutical Bulletin. 1989; 37 (7): 1844-1848. ( PubMed, DOI )

  44. Teruhiko Shimokawa, Atsuko Moriuchi, Takamitsu Hori, Masaki Saito, Yukio Naito, Hidehiro Kabasawa, Yuji Nagae, Michitaka Matsubara, Harumi Okuyama. Effect of dietary alpha-linolenate/linoleate balance on mean survival time, incidence of stroke and blood pressure of spontaneously hypertensive rats Life Sciences. 1988; 43 (25): 2067-2075. ( PubMed, DOI )

  45. Mitsuo Nakagawa, Noriyuki Ishihara, Teruhiko Shimokawa, Shoji Kojima. Effect of clofibrate on lipid peroxidation in rats treated with aspirin and 4-pentenoic acid Journal of Biochemistry. 1987.01; 101 (1): 81-88. ( PubMed, DOI )

  46. Ruth Juliet A. Villegas, Teruhiko Shimokawa, Harumi Okuyama, Mineo Kojima. Purification and characterization of chlorogenic acid: chlorogenate caffeoyl transferase in sweet potato roots Phytochemistry. 1987; 26 (6): 1577-1581. ( DOI )

  47. M. Nakagawa, T. Shimokawa, A. Noguchi, N. Ishihara, S. Kojima. Effect of clofibrate on cholesterol metabolism in rats treated with polychlorinated biphenyls Lipids. 1986.02; 21 (2): 159-163. ( PubMed, DOI )

  48. Mitsuo Nakagawa, Teruhiko Shimokawa, Shoji Kojima. Effects of Clofibrate on Hyperlipidemia Induced by Polychlorinated Biphenyls and Elimination of Polychlorinated Biphenyls Accumulated in Rat Tissues Chemical and Pharmaceutical Bulletin. 1986; 34 (9): 3940-3944. ( PubMed, DOI )

▼display all

To the head of this page.▲

Books etc 【 display / non-display 】

  1. Teruhiko Shimokawa, William L. Smith. Amino Acids Essential to Catalysis by Prostaglandin Endoperoxide Synthase. Springer Science+Business Media New York， 1991 (ISBN : 978-1-4899-0727-1)

To the head of this page.▲

Conference Activities & Talks 【 display / non-display 】

  1. T. Shimokawa, M.V.Kumar, M.D.Lane, The Johns Hopkins University School of Medicine, Department of Biological Chemistry, Baltimore, USA. Effect of the fatty acid synthase inhibitor, C75, on neuropeptide mRNA levels in hypothalamus of ob/ob mice.. Keystone Symposia 2002 at Colorado USA 2002.01.14

  2. M.V.Kumar, T. Shimokawa, M.D.Lane, The Johns Hopkins, University School of, Medicine Department of Biological Chemistry, Baltimore, USA. Chronic effects of C75, a fatty acid synthase inhibitor, in obese but not in lean mice.. Keystone Symposia 2002 at Colorado USA 2002.01.13

  3. T. Shimokawa, M.V.Kumar, M.D.Lane, The Johns Hopkins University School of Medicine, Department of Biological Chemistry, Baltimore, USA. Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides.. Keystone Symposia 2002 at Colorado USA 2002.01.12

  4. T. Shimokawa, M.V. Kumar, and M.D. Lane. Effect of a fatty acid synthase inhibitor, C75, on neuropeptide mRNA levels in hypothalamus of ob/ob mice.. Keystone Symposia 2002 at Colorado USA 2002.01.12

  5. M. Kato, Y. Watanabe, Y. Ueda, M. Ida, M. Goto, S. Nishijima, T. Shimokawa, S. Hashimoto, Molecular Medicine Laboratories, Yamanouchi Pharmaceutical Co., Ltd, Tsukuba Ibaraki Japan. Effect of thyroid hormone on muscle-specific gene regulation at mRNA level during myoblast differentiation.. The Endocrine Society, 80th Annual Meeting at New Orleans, LA, USA 1998.06.25 New Orleans, USA

  6. T. Shimokawa, M. Kato, Y. Iijima, J. Irie, K. Shioduka, Y. Ueda, M. Ida, H.-T. Ma, S. Hashimoto, O. Ezaki, Molecular Medicine Laboratories, Yamanouchi Pharmaceutical Co., Ltd, Tsukuba Ibaraki Japan, The Clinical Nutrition, The National, Institute for Health, Nutrition, Tokyo, Japan. Triiodothyronine treatment increases glucose transporter isotype 4 and MyoD mRNA levels in skeletal muscle of KK mice.. The 57th Annual Meeting of American Diabetes Association in Boston, MA (USA) 1997.07.22 Boston, USA

  7. T. Shimokawa, S. Goto, T. Ugawa, N. Hisamichi, Y. Iizumi, O. Inagaki, N. Sato, T. Takenaka, T. Kodama, Molecular Medicine Laboratories, Yamanouchi Pharmaceutical Co. Ltd, Tsukuba Ibaraki Japan, The Third Department of Internal Medicine, The University of Tokyo, Tokyo Japan. Potent hypocholesterolemic effect of YM-16638 in monkeys.. XII International Symposium on Drugs Affecting Lipid Metabolism, at Houston Texas, USA. Top 20 in the Young Investigator Award. 1995.11.08

  8. Y. Kawabe, T. Shimokawa, T. Kodama. Sterol mediated regulation of SREBP-1a, 1b, 1c and SREBP-2 in cultured human cells.. FASEB Seminar 1995

  9. W. L. Smith, T. Shimokawa, Department of Biochemistry, Michigan State University, East Lansing, MI USA. The Prostaglandin G/H Synthase. XIth Washington International Spring Symposium; "Prostaglandins, Leukotrienes, Lipoxins & PAF '91" 1991.03.15

  10. T. Shimokawa, W. L. Smith, Department of Biochemistry, Michigan State University, East Lansing, MI USA. Site-directed mutagenesis in active site serine of prostaglandin G/H synthase. The 20th Annual Michigan Cardiovascular Research Forum (AHA) 1990.09.11

▼display all

To the head of this page.▲
 

Ability of educational 【 display / non-display 】

  • Academic Partnering Activities for Practical Application - Overseas Practice，2022.03

To the head of this page.▲

Performance of duties 【 display / non-display 】

  • Industry-Government-Academia Drug Discovery School "Learning Translational Research for Drug Discovery for Neurological Diseases" sponsored by the Japan Neurological Society，2024.02

  • ，2023.03 - 2024.06

  • Cutting-edge Bioimaging AI Research Consortium，2022.08 - 2023.09

  • ，2022.05

  • AMED Open seminar; Practical course for practitioners of overseas business meetings.，2022.03

To the head of this page.▲